OA/US: How this New Hybrid Modality Can Impact Your Patients
Tuesday, June 7, 2022, 2:00 PM ET
Certification: Approved for 1.0 ARRT Category A CE credit by the AHRA
(AHRA Reference: LEC11689; Expiration Date: 6/8/2023)
Presented by:
A. Thomas Stavros, M.D., F.A.C.R., F.S.R.U., F.S.B.I, Chief Medical Officer, Seno Medical
Join Dr. A. Thomas Stavros, Chief Medical Officer at Seno Medical for a 60-minute webinar to learn how this new PMA approved hybrid modality uses opto-acoustics (lasers) fused with ultrasound (OA/US) to provide your patients a better experience providing superiority over ultrasound alone.
Sponsored by:
Seno Medical
ICE Webinars would like to thank our sponsor, Seno Medical! Seno Medical is a medical imaging company formed to commercialize a new modality in cancer diagnosis called opto-acoustic imaging. A strong, experienced management team and nationally recognized Medical Advisory Board have been assembled to complete the commercialization, secure regulatory approval and launch the products. The management team has a long history of developing successfully commercialized medical devices.
